Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Seltorexant Formulations in Healthy Participants
NCT04553042Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of seltorexant in major depressive disorder (MDD) and Insomnia (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration at 48 hours, Last Observed Measurable Plasma Concentration at 48 hours and 3 more. Started Sep 2020; status: completed.
02
Drugs
seltorexant
03
Conditions
major depressive disorder (MDD)Insomnia
Beyond the preview
Go deeper on NCT04553042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04553042.